DANVERS, Mass., Nov. 13, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that its Board of Directors has authorized a stock repurchase program of up to $15 million of its common stock.
